Ad hoc: Biofrontera AG: Distribution Agreement with Pelpharma Handels GmbH for Ameluz® in Austria
(Thomson Reuters ONE) -
Biofrontera AG /
Ad hoc: Biofrontera AG: Distribution Agreement with Pelpharma Handels GmbH for
Ameluz® in Austria
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 13 August 2012 - Biofrontera Pharma GmbH, a fully-owned subsidiary
of Biofrontera AG, has today signed an exclusive agreement with Pelpharma
Handels GmbH in Vienna, Austria, for the marketing of Ameluz(®) in Austria. In
December 2011 Ameluz(®) received a centralized European approval as medicinal
product for the first-line treatment of mild and moderate actinic keratosis in
the face and on the scalp.
Pelpharma is a pharmaceutical company entirely focused on the Austrian
dermatology market. The company distributes several medicinal products in
Austria with own approvals or licensed from other Pharma companies. Over the
years, Pelpharma's employees have developed close contacts to Austrian
dermatologists.
Pelpharma will purchase Ameluz® from Biofrontera at 55% of Pelpharma's net
selling price. Biofrontera will take responsibility for manufacturing and
pharmacolvigilance. The Austrian launch in selected hospitals is anticipated
shortly, with practicing dermatologists in November 2012.
Ameluz® is used in photodynamic therapy, which thus far in Austria is applied
only rarely and almost exclusively in hospitals. Biofrontera has decided to work
together with Pelpharma particularly because of the established relationships
this company has to Austrian dermatologists, which are particularly relevant for
the establishment of photodynamic therapy with practicing dermatologists.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Anke zur Mühlen
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: a.zurmuehlen(at)biofrontera.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1633456]
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2012 - 10:49 Uhr
Sprache: Deutsch
News-ID 173811
Anzahl Zeichen: 2656
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 140 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: Biofrontera AG: Distribution Agreement with Pelpharma Handels GmbH for Ameluz® in Austria"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
